PET-CT Predicting Lymph Nodes Metastasis

The Value of PET-CT in Predicting Lymph Nodes Metastasis in Non Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05970913

Enrollment

280

Registered

2023-08-01

Start date

2023-11-01

Completion date

2026-03-28

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymph Node Metastasis, Non Small Cell Lung Cancer, Positron Emission Tomography

Brief summary

This study is a single-center prospective clinical study that aims to evaluate the predictive value of preoperative 18F-FDG-PET-CT and 18F-FAPI-PET/CT for lymph node metastasis in patients with non-small cell lung cancer. The final pathological results were used to assess the predictive value of PET-CT for lymph node metastasis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion. * Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1. * Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery. * No prior radiotherapy or chemotherapy for initial treatment. * No history of malignant tumors.

Exclusion criteria

* Locally advanced or distant metastasis. * Pleural dissemination observed during surgery. * History of malignant tumors. * Received neoadjuvant therapy. * Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).

Design outcomes

Primary

Measure	Time frame
Predictive value of 18F-FDG-PET/CT and 18F-FAPI-PET/CT for lymph node metastasis	from enrollment to 1 month after surgery

Countries

China

Outcome results